酒石酸唑吡坦对比阿普唑仑辅助治疗抑郁症睡眠障碍  

Comparison of Zolpidem Tartrate With Alprazolam in Adjuvant Treatment of Depression Sleep Disorder

作　　者：汪萍[1] 方明[1] 向会尧 宋承伟[1] 

机构地区：[1]三峡大学人民医院神经内科,湖北宜昌443000

出　　处：《中国继续医学教育》2016年第12期154-155,共2页China Continuing Medical Education

摘　　要：目的比较酒石酸唑吡坦与阿普唑仑辅助治疗抑郁症睡眠障碍的疗效和安全性。方法 86例抑郁症合并睡眠障碍患者随机分为两组,观察组采用酒石酸唑吡坦辅助治疗,对照组采用阿普唑仑辅助治疗,采用汉密尔顿抑郁量表(HAMD)、匹兹堡睡眠质量指数量表(PSQI)评定疗效。结果治疗2个月后,观察组有效率为95.35%高于对照组的88.37%(P<0.05);观察组组治疗后HAMD及PSQI评分低于对照组(P<0.01)。结论酒石酸唑吡坦治疗抑郁症睡眠障碍相比阿普唑仑治疗效果更好,可有效降低抑郁心理且不良反应较低。Objective To compare efficacy and safety of zolpidem tartrate and alprazolam in the treatment of depression sleep disorders. Methods 86 cases of depression with sleep disorders were randomly divided into two groups, the observation group used zolpidem tartrate adjuvant therapy, the control group used alprazolam adjuvant therapy. Hamilton Depression Scale（HAMD）, Pittsburgh Sleep Quality Index scale（PSQI） were used to evaluate the efficacy. Results After 2 months of treatment, the effective rate was 95.35% in the observation group was significantly higher than 88.37%（P〈0.05）, the observation group after group after treatment HAMD and PSQI scores were significantly lower than the control group（P〈0.01）. Conclusion Zolpidem tartrate in treating depression sleep disorder phase is better than alprazolam, can effectively reduce the mental depression and lower adverse reactions.

关 键 词：抑郁症 睡眠障碍 酒石酸唑吡坦 

分 类 号：R971[医药卫生—药品]